Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma

References

• From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011 (accessed date: December 2011). Available from:http://www.ginasthma.org/.
   Google Scholar
• Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910–917.
   Google Scholar
• Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: A 1-yr prospective study. Eur Respir J 2002; 19:61–67.
   PubMed Web of Science ®Google Scholar
• Stirling RG, Chung KF. Severe asthma: Definition and mechanisms. Allergy 2001; 56:825–840.
   PubMedGoogle Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Omalizumab Gupta N. anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184–190.
   Google Scholar
• Buhl R, Soler M, Matz J, Townley R, O’Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20:73–78.
   Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Effectiveness and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to severe) allergic asthma. Allergy 2004; 59:701–708.
   PubMed Web of Science ®Google Scholar
• Bavbek S, Aydın O, Kepil Özdemir S, Yılmaz I, Celik GE, Demirel YS, Mungan D, Sin B, Kurşun N, Mısırlıgil Z. Therapy with omalizumab in patients with severe persistent allergic asthma: A real life data in Turkey. Tuberk Toraks 2010; 58:425–434.
   PubMedGoogle Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med 2011; 154:573–582.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils O, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham K, MacDonald I. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103:1633–1642.
   Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Italian real-life experience of omalizumab. Respir Med 2010: 104:1410–1416.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C. Spanish RegistryOmalizumab therapy in severe asthma: Experience from the Spanish registry—some new approaches. J Asthma 2012; 49:416–422.
   PubMed Web of Science ®Google Scholar
• Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: Real-life experience in Israel. J Asthma 2012; 49:78–82.
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, Kroegel C. Omalizumab in patients with severe asthma: The XCLUSIVE study. Clin Respir J 2012; 6s:215–227.
   Google Scholar
• Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102:71–76.
   PubMed Web of Science ®Google Scholar
• Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma 2011; 48:387–392.
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N Siafakas NM. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012; 25:77–82.
   Google Scholar
• Storms W, Bowdish MS, Farrar JR. Omalizumab and asthma control in patients with moderrate-to-severe allergic asthma: A 6-year pragmatic data review. Allergy Asthma Proc 2012; 33:172–177.
   PubMed Web of Science ®Google Scholar
• Nopp A, Johansson SGO, Adedoyin J, Ankerst J, Palmqvist M, Öman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56–60.
   PubMed Web of Science ®Google Scholar
• Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, Castagnetti C, Carbonelli C, Zucchi L. Clinical and pharmacoeconomic aspects of omalizumab: A 4-year follow-up. Ther Adv Respir Dis 2012; 6:87–95.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012; 49:843–848.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention, 2006. NHI Publications No 02-3659.
   Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59–65.
   Google Scholar
• Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115(5):1265–1270.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A ve ark. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47:81–87.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K., Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
   Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, QUALITX Study Investigators. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: A Brazilian study (QUALITX). J Asthma 2012; 49:288–293.
   PubMed Web of Science ®Google Scholar